Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 1257 results for "ranbaxy"

Buy Ranbaxy Laboratories: Jitendra Panda

Jitendra Panda of Peerless Securities recommends buying Ranbaxy Laboratories as the stock may test Rs 500. Money Control, 10 hours ago

912 images for ranbaxy

India TV, 3 days ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago
Rediff.com, 1 day ago

Buy Ranbaxy at a target of Rs 499: Sandeep Wagle

Follow this section for latest news on Views/Recommendations EmailRSS Have something to say? Post your comment Comments are moderated and will be allowed if they are about the topic and not abusive. Characters remaining ( 1500 ) To post this comment you must ...
 Economic Times12 hours ago

BEARING RANBAXY BURDEN

The takeover of Daiichi Sankyo owned Ranbaxy Labs by Sun Pharmaceuticals for $4 billion including a $800 million liability early this month surprised quite a few in the Indian pharmaceutical industry. There was hardly any indication of such a move ...
 PharmaBiz16 hours ago
Deccan Chronicle

Ranbaxy's journey as a...

Ranbaxy Laboratories will cease to exist as a company after completion of the USD 4 billion merger with Sun Pharmaceuticals, although its brands will be kept alive in over 100 markets. "The Ranbaxy entity will be merged into Sun Pharma and Sun ...
 Siasat Daily2 days ago Sun to merge Ranbaxy, to keep brands alive  Deccan Chronicle2 days ago Ranbaxy will cease to exist after merger with Sun Pharma  Space View Times3 days ago Ranbaxy's journey as a company to end after merger with Sun Pharma  NDTV Profit3 days ago
[x]  
Business Today India

Sebi smells rat in Sun Pharma-Ranbaxy deal

Sun Pharmaceutical Industries surged another seven per cent on Wednesday but the company came under a cloud as multiple complaints of alleged insider trading in Ranbaxy shares before the announcement of the $3.2- billion takeover have been lodged ...
 Business Today India1 week ago Dalal Street questions Ranbaxy spike  Times of India1 week ago Ranbaxy share trading under SEBI scanner  VC Circle2 weeks ago Brokers' association to ask Sebi to investigate Ranbaxy trades  Business Standard2 weeks ago
[x]  
Reuters India

Ranbaxy Drugs to be Rebranded as Sun Pharma to Help U.S. Reputation

According to Reuter's sources, Sun Pharmaceutical Industries will begin phasing out sales of generic drugs branded as Ranbaxy Laboratories in the United States, following Sun's $3.2 billion aquisition of Ranbaxy in early April. The rebranding of ...
 Pharmaceutical Manufacturing Magazine5 days ago Sun plans gradual phase-out of ranbaxy-branded drugs in us  4 Traders1 week ago Ranbaxy drugs in US to be phased out  Smart Investor1 week ago Sun To Phase Out Ranbaxy Drugs In US  Businessworld India2 weeks ago
[x]  
Finance 24

Investors back Sun Pharma's Ranbaxy move (AFP)

On the surface, Sun Pharma's $US3.2 billion ($A3.42 billion) purchase of Indian generics rival Ranbaxy, which is in deep trouble with US regulators over safety lapses, may not look like a great deal. But Sun Pharmaceutical Industries' shares ...
 West Australian1 week ago Sun Pharma is able to revive Ranbaxy: investors  China Post1 week ago Investors hail Sun Pharma's Ranbaxy buy  Qatar Peninsula1 week ago 'Sun Pharma can nurse Ranbaxy to health'  Finance 241 week ago
[x]  
Livemint.com

Ranbaxy, Samsung, Zillow, Scotch: Intellectual Property

A gap in U.S. patent law has kept cheap copies of Novartis AG's (NOVN) heart drug Diovan off the market for 18 months, costing U.S. consumers and insurers as much as $900 million in potential savings. While the Diovan patent expired in September ...
 Bloomberg1 week ago Ranbaxy's Woes Add $900 Million to U.S. Heart Drug Costs  Bloomberg1 week ago Ranbaxy, Samsung, Zillow, Scotch Whisky: Intellectual Property  BusinessWeek1 week ago Ranbaxy's woes add $900 million in costs for heart drug  Livemint.com1 week ago
[x]  
Business Standard

Is Dilip Shanghvi's big bet worth the risk?

Ranbaxy's frequent run-ins with the US FDA may have proved too much for its previous owner, Japan's Daiichi Sankyo, but for Sun Pharma, it is an astute purchase that it hopes will not only boost its position in India but also globally Reghu Balakrishnan | ...
 Business Standard2 days ago

Nischal Maheshwari neutral on pharmaceutical space

N Within that, there are a lot of stocks which we like. The Sun Pharmaceutical - Ranbaxy deal has been quite an outflier. That is the stock on a one-two year horizon we have been recommending to our clients. Similarly, Dr Reddy's Laboratories , ...
 Moneycontrol.com2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less